Biogen Inc.
BIIB
Rank in Stocks
#683
Biogen Inc. is a leading biotechnology firm dedicated to the discovery,... Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$242.79
Last synced: 2026-10-20
Market Cap
$35.87B
Change (1 day)
3.99%
Change (1 year)
66.04%
Country
US
Trade Biogen Inc. (BIIB)
Category
Healthcare
Revenue for Biogen Inc. (BIIB)
Revenue in Jun 2026 TTM: $9.95B
According to Biogen Inc. latest financial reports the company's current revenue (TTM) is $9.95B. In 2024 the company made a revenue of $9.68B a decrease compared to the revenue in the year 2023 that was $9.84B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Biogen Inc. from 2000 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $9.95B | 1.40% |
| 2025 | $9.81B | 1.39% |
| 2024 | $9.68B | -1.62% |
| 2023 | $9.84B | -3.32% |
| 2022 | $10.17B | -7.36% |
| 2021 | $10.98B | -18.32% |
| 2020 | $13.44B | -6.49% |
| 2019 | $14.38B | 6.88% |
| 2018 | $13.45B | 9.61% |
| 2017 | $12.27B | 7.21% |
| 2016 | $11.45B | 6.36% |
| 2015 | $10.76B | 10.93% |
| 2014 | $9.70B | 39.97% |
| 2013 | $6.93B | 25.70% |
| 2012 | $5.51B | 9.23% |
| 2011 | $5.05B | 7.04% |
| 2010 | $4.72B | 7.75% |
| 2009 | $4.38B | 6.83% |
| 2008 | $4.10B | 29.19% |
| 2007 | $3.17B | 18.21% |
| 2006 | $2.68B | 56.57% |
| 2005 | $1.71B | 7.38% |
| 2004 | $1.60B | 757.35% |
| 2003 | $186.13M | -53.95% |
| 2002 | $404.22M | -61.22% |
| 2001 | $1.04B | 12.60% |
| 2000 | $925.67M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $79.67B | 700.83% |
US
|
|
| $99.34B | 898.55% |
US
|
|
| $64.39B | 547.23% |
US
|
|
| $66.40B | 567.48% |
US
|
|
| $77.52B | 679.25% |
CH
|
